Blog
RSS FeedPosted by Michael Wonder on 22 Oct 2024
ICER publishes final evidence report on treatments for transthyretin amyloid cardiomyopathy
21 October 2024 - Independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ...
Posted by Michael Wonder on 17 Sep 2024
ICER to assess treatment for retinitis pigmentosa
17 September 2024 - Report will be subject of New England CEPAC meeting in April 2025; draft scoping document open ...
Posted by Michael Wonder on 09 Aug 2024
BioMarin announces updated strategy for Roctavian to focus on US, Germany and Italy
5 August 2024 - Strategic focus will reduce operating expenses with the goal of achieving Roctavian profitability by end of 2025. ...
Posted by Michael Wonder on 23 Apr 2024
ICER and NEWDIGS release white paper analysing the challenges and potential policy options for paying for gene therapies
23 April 2024 - Paper outlines policy reforms and market actions to support innovation and access while managing uncertainty, affordability, ...
Posted by Michael Wonder on 30 Oct 2023
ICER publishes final evidence report on gene therapy for metachromatic leukodystrophy
30 October 2023 - Independent appraisal committee voted that across all patient sub-populations, arsa-cel demonstrated a net health benefit when ...
Posted by Michael Wonder on 14 Sep 2023
ICER publishes evidence report on gene therapy for metachromatic leukodystrophy
14 September 2023 - Using weighted analyses across all patient subpopulations, atidarsagene autotemcel would achieve common thresholds for cost effectiveness if priced ...
Posted by Michael Wonder on 21 Aug 2023
ICER publishes final evidence report on gene therapies for sickle cell disease
21 August 2023 - Current evidence suggests that lovo-cel and exa-cel would achieve common thresholds for cost-effectiveness if priced between $1.35 ...
Posted by Michael Wonder on 13 Jul 2023
ICER publishes evidence report on gene therapies for sickle cell disease
13 July 2023 - In the short term, both lovo-cel and exa-cel can dramatically reduce the frequency of painful crises ...
Posted by Michael Wonder on 03 Jun 2023
America will struggle to pay for ultra-expensive gene therapies
1 June 2023 - The drugs may force reform to Medicaid. ...
Posted by Michael Wonder on 12 Apr 2023
ICER releases draft evidence report on gene therapies for sickle cell disease
12 April 2023 - Public comment period now open until 9 May 2023; Requests to make oral comment during public ...
Posted by Michael Wonder on 10 Mar 2023
ICER to assess gene therapy for metachromatic leukodystrophy
9 March 2023 - Report will be subject of CTAF meeting in September 2023; draft scoping document open to public ...
Posted by Michael Wonder on 22 Dec 2022
ICER publishes final evidence report on gene therapies for haemophilia A and B
22 December 2022 - Fair pricing benchmarks suggest upper bounds for price of Roctavian at approximately $1.9 million and for Hemgenix ...
Posted by Michael Wonder on 23 Nov 2022
ICER to assess gene therapies for sickle cell disease
23 November 2022 - Report will be subject of CTAF meeting in June 2023; draft scoping document open to public ...
Posted by Michael Wonder on 02 Nov 2022
ICER publishes evidence report on gene therapies for haemophilia A and B
2 November 2022 - Duration of benefit with gene therapies and risks for rare side effects remain major uncertainties. ...
Posted by Michael Wonder on 13 Sep 2022
ICER releases draft evidence report on gene therapies for haemophilia A and B
13 September 2022 - Registration now open for 20 September “Early Insights” webinar. ...